USE OF THYROID BETA-AGONISTS

• US 20190321379A1
• Filed: 04/24/2017
• Published: 10/24/2019
• Est. Priority Date: 04/22/2016
• Status: Active Grant

• Current Assignee: Metabasis Therapeutics, Inc. (Ligand Pharmaceuticals, Inc.), Viking Therapeutics, Inc.
• Original Assignee: Hongjian Jiang, Metabasis Therapeutics, Inc. (Ligand Pharmaceuticals, Inc.), Viking Therapeutics, Inc.
• Inventors: Lian, Brian, Hanley, Rochelle, Dinerman, Misha, Erion, Mark, Boyer, Serge, Jiang, Hongjian
• Granted Patent: US 11,351,183 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 31/662 Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
• CPC Class Codes: A61K 31/665 having oxygen as a ring hetero atom, e.g. fosfomycin
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/38 of the suprarenal hormones

Abstract

Methods useful for treating X-linked adrenoleukodystrophy are provided.

Claims

1. A method for treating X-linked adrenoleukodystrophy, comprising administering to a subject a compound having the structure

2. The method of claim 1, wherein the compound is

3. The method of claim 2, wherein the compound is

4. The method of claim 1, wherein the compound is

5. The method of claim 4, wherein the compound is

6. The method of claim 1, wherein the compound is administered at a dose of between about 1 mg and about 100 mg per day.

7. The method of claim 1, wherein the compound is administered daily, every other day, or intermittently for three months followed by a period of time from about 2 months to about 1 week when the compound is not administered.

8. The method of claim 6, wherein the compound is administered at a dose of between about 1 mg and about 50 mg per day.

9. The method of claim 8, wherein the compound is administered at a dose of between about 1 mg and about 25 mg per day.

10. The method of claim 1, wherein the compound is administered at a dose of 100 mg/day, 50 mg/day, 25 mg/day, 20 mg/day, 15 mg/day, 10 mg/day, 5 mg/day, or 1 mg/day.

11. The method of claim 10, wherein the compound is administered at a dose of 5 mg/day, 10 mg/day, or 15 mg/day.

12. The method of claim 10, wherein the compound is administered at a dose of 5 mg/day.

13. The method of claim 10, wherein the compound is administered at a dose of 10 mg/day.

14. The method of claim 1, wherein the compound is administered at a dose of between about 1 mg and about 100 mg every other day.

15. The method of claim 14, wherein the compound is administered at a dose of between about 1 mg and about 50 mg every other day.

16. The method of claim 14, wherein the compound is administered at a dose of between about 1 mg and about 25 mg every other day.

17. The method of claim 1, wherein the compound is administered at a dose of 10 mg every other day or 15 mg every other day.

18. The method of claim 1, wherein the compound is administered daily, every other day, or intermittently for three months followed by a period of time of one month when the thyroid hormone receptor beta agonist is not administered.

19. The method of claim 1, wherein the compound is administered daily, every other day, or intermittently for three months followed by a period of time of 14 days when the thyroid hormone receptor beta agonist is not administered.

20. The method of claim 1, wherein the compound is administered daily, every other day, or intermittently for two months followed by a period of time of one month when the thyroid hormone receptor beta agonist is not administered.